Pharmacogenetics in psychiatry - A useful clinical tool or wishful thinking for the future?

Current Pharmaceutical Design

Volumn 16, Issue 2, 2010, Pages 136-144

  Kirchheiner, J ^a   Seeringer, A ^a   Viviani, R ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

CYP2D6; Pharmacogenomics; Psychiatry; Serotonin transporter

Indexed keywords

ABACAVIR; ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; AZATHIOPRINE; BIOLOGICAL MARKER; CITALOPRAM; DRUG METABOLIZING ENZYME; FLUOXETINE; FLUVOXAMINE; ISONIAZID; NORTRIPTYLINE; PAROXETINE; PROTON PUMP INHIBITOR; PSYCHOTROPIC AGENT; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

CLINICAL ASSESSMENT; CLINICAL PRACTICE; CLINICAL TRIAL; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG RESPONSE; DRUG TARGETING; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MEDICAL DECISION MAKING; NEUROIMAGING; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; PSYCHIATRY; REMISSION; REVIEW; RISK BENEFIT ANALYSIS;

CYTOCHROME P-450 CYP2D6; DOSE-RESPONSE RELATIONSHIP, DRUG; GENOTYPE; HUMANS; MENTAL DISORDERS; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, GENETIC; PSYCHIATRY; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TREATMENT OUTCOME;

EID: 77949461421     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210790112728     Document Type: Review

References (104)

1. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286(5439): 487-91.
2. Bertilsson L, Dahl ML, Dalen P, Al-Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002; 53(2): 111-22.
3. Sachse C, Brockmöller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60(2): 284-95.
4. Zanger UM, Fischer J, Raimundo S, Stuven T, Evert BO, Schwab M, et al. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 2001; 11(7): 573-85.
5. Griese EU, Zanger UM, Brudermanns U, Gaedigk A, Mikus G, Morike K, et al. Assessment of the predictive power of genotypes for the in vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 1998; 8(1): 15-26.
6. Gaedigk A, Ndjountche L, Divakaran K, Bradford DL, Zineh I, Oberlander TF, et al. Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity: characterization of gene duplication events. Clin Pharmacol Ther 2007; 81(2): 242-51.
7. Kirchheiner J, Fuhr U, Brockmoller J. Pharmacogenetics-based therapeutic recommendations - ready for clinical practice? Nat Rev Drug Discov 2005; 4(8): 639-47.
8. Kirchheiner J, Brosen K, Dahl ML, Gram LF, Kasper S, Roots I, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001; 104(3): 173-92.
9. McLeod HL, Siva C. The thiopurine S-methyltransferase gene locus - implications for clinical pharmacogenomics. Pharmacogenomics 2002; 3(1): 89-98.
10. Wu AH, Wang P, Smith A, Haller C, Drake K, Linder M, et al. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. Pharmacogenomics 2008; 9(2): 169-78.
11. Wen MS, Lee M, Chen JJ, Chuang HP, Lu LS, Chen CH, et al. Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. Clin Pharmacol Ther 2008; 84(1): 83-9.
12. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005; 106(7): 2329-33.
13. Katz MM, Tekell JL, Bowden CL, Brannan S, Houston JP, Berman N, et al. Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacology 2004; 29(3): 566-79.
14. Trivedi MH, Morris DW, Grannemann BD, Mahadi S. Symptom clusters as predictors of late response to antidepressant treatment. J Clin Psychiatry 2005; 66(8): 1064-70.
15. Troost PW, Lahuis BE, Hermans MH, Buitelaar JK, van Engeland H, Scahill L, et al. Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism. J Clin Psychopharmacol 2007; 27(1): 52-7.
16. Bork JA, Rogers T, Wedlund PJ, de Leon J. A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. J Clin Psychiatry 1999; 60(7): 469-76.
17. Shams ME, Arneth B, Hiemke C, Dragicevic A, Muller MJ, Kaiser R, et al. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther 2006; 31(5): 493-502.
18. Lessard E, Yessine M, Hamelin B, O'Hara G, LeBlanc J, Turgeon J. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics 1999; 9: 435-43.
19. Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M, et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 2008; 57(2): 203-9.
20. Grossman I. Routine pharmacogenetic testing in clinical practice: dream or reality? Pharmacogenomics 2007; 8(10): 1449-59.
21. de Leon J. The future (or lack of future) of personalized prescription in psychiatry. Pharmacol Res 2009; 59(2): 81-9.
22. de Leon J. Pharmacogenomics: the promise of personalized medicine for CNS disorders. Neuropsychopharmacology 2009; 34(1): 159-72.
23. Arranz MJ, Kapur S. Pharmacogenetics in psychiatry: are we ready for widespread clinical use? Schizophr Bull 2008; 34(6): 1130-44.
24. Broich K, Moller HJ. Pharmacogenetics, pharmacogenomics and personalized psychiatry: are we there yet? Eur Arch Psychiatry Clin Neurosci 2008; 258 (Suppl 1): 1-2.
25. Serretti A, Kato M, Kennedy JL. Pharmacogenetic studies in depression: a proposal for methodologic guidelines. Pharmacogenomics J 2008; 8(2): 90-100.
26. Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 2008 [Epub ahead of print].
27. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996; 274(5292): 1527-31.
28. Rausch JL, Johnson ME, Fei YJ, Li JQ, Shendarkar N, Hobby HM, et al. Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome. Biol Psychiatry 2002; 51(9): 723-32.
29. Yu YW, Tsai SJ, Chen TJ, Lin CH, Hong CJ. Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry 2002; 7(10): 1115-9.
30. Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 1998; 3(6): 508-11.
31. Zanardi R, Serretti A, Rossini D, Franchini L, Cusin C, Lattuada E, et al. Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol Psychiatry 2001; 50(5): 323-30.
32. Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA, et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000; 23(5): 587-90.
33. Pollock BG, Laghrissi-Thode F, Wagner WR. Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. J Clin Psychopharmacol 2000; 20(2): 137-40.
34. Zanardi R, Benedetti F, Di Bella D, Catalano M, Smeraldi E. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol 2000; 20(1): 105-7.
35. Benedetti F, Serretti A, Colombo C, Campori E, Barbini B, di Bella D, et al. Influence of a functional polymorphism within the promoter of the serotonin transporter gene on the effects of total sleep deprivation in bipolar depression. Am J Psychiatry 1999; 156(9): 1450-2.
36. Smits KM, Smits LJ, Peeters FP, Schouten JS, Janssen RG, Smeets HJ, et al. The influence of 5-HTTLPR and STin2 polymorphisms in the serotonin transporter gene on treatment effect of selective serotonin reuptake inhibitors in depressive patients. Psychiatr Genet 2008; 18(4): 184-90.
37. Kraft JB, Peters EJ, Slager SL, Jenkins GD, Reinalda MS, McGrath PJ, et al. Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample. Biol Psychiatry 2007; 61(6): 734-42.
38. Hu XZ, Rush AJ, Charney D, Wilson AF, Sorant AJ, Papanicolaou GJ, et al. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch Gen Psychiatry 2007; 64(7): 783-92.
39. Serretti A, Cusin C, Rausch JL, Bondy B, Smeraldi E. Pooling pharmacogenetic studies on the serotonin transporter: a mega-analysis. Psychiatry Res 2006; 145(1): 61-5.
40. Smits KM, Smits LJ, Schouten JS, Stelma FF, Nelemans P, Prins MH. Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review. Mol Psychiatry 2004; 9(5): 433-41.
41. Rasmussen-Torvik LJ, McAlpine DD. Genetic screening for SSRI drug response among those with major depression: great promise and unseen perils. Depress Anxiety 2007; 24(5): 350-7.
42. Wong ML, Dong C, Maestre-Mesa J, Licinio J. Polymorphisms in inflammation-related genes are associated with susceptibility to major depression and antidepressant response. Mol Psychiatry 2008; 13(8): 800-12.
43. Esposito K, Reierson GW, Luo RH, Wu SG, Licinio J, Wong ML. Phosphodiesterase genes and antidepressant treatment response: A review. Ann Med 2008; 41(3): 177-85.
44. Tsai SJ, Hong CJ, Liou YJ. Brain-derived neurotrophic factor and antidepressant action: another piece of evidence from pharmacogenetics. Pharmacogenomics 2008; 9(9): 1353-8.
45. Ribeiro L, Busnello JV, Cantor RM, Whelan F, Whittaker P, Deloukas P, et al. The brain-derived neurotrophic factor rs6265 (Val66Met) polymorphism and depression in Mexican-Americans. Neuroreport 2007; 18(12): 1291-3.
46. Prathikanti S, Weinberger DR. Psychiatric genetics - the new era: genetic research and some clinical implications. Br Med Bull 2005; 73-74: 107-22.
47. Abdolmaleky HM, Thiagalingam S, Wilcox M. Genetics and epigenetics in major psychiatric disorders: dilemmas, achievements, applications, and future scope. Am J Pharmacogenomics 2005; 5(3): 149-60.
48. Weiss ST, McLeod HL, Flockhart DA, Dolan ME, Benowitz NL, Johnson JA, et al. Creating and evaluating genetic tests predictive of drug response. Nat Rev Drug Discov 2008; 7(7): 568-74.
49. Krekels EH, van den Anker JN, Baiardi P, Cella M, Cheng KY, Gibb DM, et al. Pharmacogenetics and paediatric drug development: issues and consequences to labelling and dosing recommendations. Expert Opin Pharmacother 2007; 8(12): 1787-99.
50. Gottesman, II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003; 160(4): 636-45.
51. Wagner JA, Williams SA, Webster CJ. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin Pharmacol Ther 2007; 81(1): 104-7.
52. Hasler G, Drevets WC, Manji HK, Charney DS. Discovering endophenotypes for major depression. Neuropsychopharmacology 2004; 29(10): 1765-81.
53. Bell C, Abrams J, Nutt D. Tryptophan depletion and its implications for psychiatry. Br J Psychiatry 2001; 178: 399-405.
54. Rogers RD, Tunbridge EM, Bhagwagar Z, Drevets WC, Sahakian BJ, Carter CS. Tryptophan depletion alters the decision-making of healthy volunteers through altered processing of reward cues. Neuropsychopharmacology 2003; 28(1): 153-62.
55. Cools R. Role of dopamine in the motivational and cognitive control of behavior. Neuroscientist 2008; 14(4): 381-95.
56. Robbins TW. Synthesizing schizophrenia: a bottom-up, symptomatic approach. Schizophr Bull 2005; 31(4): 854-64.
57. Strange BA, Hurlemann R, Dolan RJ. An emotion-induced retrograde amnesia in humans is amygdala- and beta-adrenergic-dependent. Proc Natl Acad Sci USA 2003; 100(23): 13626-31.
58. Meyer-Lindenberg A, Weinberger DR. Intermediate phenotypes and genetic mechanisms of psychiatric disorders. Nat Rev Neurosci 2006; 7(10): 818-27.
59. Drevets WC. Neuroimaging studies of mood disorders. Biol Psychiatry 2000; 48(8): 813-29.
60. Mayberg HS. Positron emission tomography imaging in depression: a neural systems perspective. Neuroimaging Clin N Am 2003; 13(4): 805-15.
61. Drevets WC, Videen TO, Price JL, Preskorn SH, Carmichael ST, Raichle ME. A functional anatomical study of unipolar depression. J Neurosci 1992; 12(9): 3628-41.
62. Whalen PJ, Shin LM, Somerville LH, McLean AA, Kim H. Functional neuroimaging studies of the amygdala in depression. Semin Clin Neuropsychiatry 2002; 7(4): 234-42.
63. Drevets WC, Price JL, Bardgett ME, Reich T, Todd RD, Raichle ME. Glucose metabolism in the amygdala in depression: relationship to diagnostic subtype and plasma cortisol levels. Pharmacol Biochem Behav 2002; 71(3): 431-47.
64. Morris JS, Frith CD, Perrett DI, Rowland D, Young AW, Calder AJ, et al. A differential neural response in the human amygdala to fearful and happy facial expressions. Nature 1996; 383(6603): 812-5.
65. Sheline YI, Barch DM, Donnelly JM, Ollinger JM, Snyder AZ, Mintun MA. Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an fMRI study. Biol Psychiatry 2001; 50(9): 651-8.
66. Siegle GJ, Steinhauer SR, Thase ME, Stenger VA, Carter CS. Can't shake that feeling: event-related fMRI assessment of sustained amygdala activity in response to emotional information in depressed individuals. Biol Psychiatry 2002; 51(9): 693-707.
67. Drevets WC, Price JL, Simpson JR Jr, Todd RD, Reich T, Vannier M, et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature 1997; 386(6627): 824-7.
68. Mayberg HS, Liotti M, Brannan SK, McGinnis S, Mahurin RK, Jerabek PA, et al. Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. Am J Psychiatry 1999; 156(5): 675-82.
69. Abler B, Hofer C, Viviani R. Habitual emotion regulation strategies and baseline brain perfusion. Neuroreport 2008; 19(1): 21-4.
70. Kegeles LS, Malone KM, Slifstein M, Ellis SP, Xanthopoulos E, Keilp JG, et al. Response of cortical metabolic deficits to serotonergic challenge in familial mood disorders. Am J Psychiatry 2003; 160(1): 76-82.
71. Sotres-Bayon F, Bush DE, LeDoux JE. Emotional perseveration: an update on prefrontal-amygdala interactions in fear extinction. Learn Mem 2004; 11(5): 525-35.
72. Phillips ML, Drevets WC, Rauch SL, Lane R. Neurobiology of emotion perception I: The neural basis of normal emotion perception. Biol Psychiatry 2003; 54(5): 504-14.
73. Brody AL, Saxena S, Silverman DH, Alborzian S, Fairbanks LA, Phelps ME, et al. Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine. Psychiatry Res 1999; 91(3): 127-39.
74. Drevets WC, Bogers W, Raichle ME. Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism. Eur Neuropsychopharmacol 2002; 12(6): 527-44.
75. Buchsbaum MS, Wu J, Siegel BV, Hackett E, Trenary M, Abel L, et al. Effect of sertraline on regional metabolic rate in patients with affective disorder. Biol Psychiatry 1997; 41(1): 15-22.
76. Holthoff VA, Beuthien-Baumann B, Zundorf G, Triemer A, Ludecke S, Winiecki P, et al. Changes in brain metabolism associated with remission in unipolar major depression. Acta Psychiatr Scand 2004; 110(3): 184-94.
77. Kennedy SH, Konarski JZ, Segal ZV, Lau MA, Bieling PJ, McIntyre RS, et al. Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial. Am J Psychiatry 2007; 164(5): 778-88.
78. Mayberg HS, Brannan SK, Tekell JL, Silva JA, Mahurin RK, McGinnis S, et al. Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol Psychiatry 2000; 48(8): 830-43.
79. Martin SD, Martin E, Rai SS, Richardson MA, Royall R. Brain blood flow changes in depressed patients treated with interpersonal psychotherapy or venlafaxine hydrochloride: preliminary findings. Arch Gen Psychiatry 2001; 58(7): 641-8.
80. Little JT, Ketter TA, Kimbrell TA, Dunn RT, Benson BE, Willis MW, et al. Bupropion and venlafaxine responders differ in pretreatment regional cerebral metabolism in unipolar depression. Biol Psychiatry 2005; 57(3): 220-8.
81. Mayberg HS, Brannan SK, Mahurin RK, Jerabek PA, Brickman JS, Tekell JL, et al. Cingulate function in depression: a potential predictor of treatment response. Neuroreport 1997; 8(4): 1057-61.
82. Canli T, Cooney RE, Goldin P, Shah M, Sivers H, Thomason ME, et al. Amygdala reactivity to emotional faces predicts improvement in major depression. Neuroreport 2005; 16(12): 1267-70.
83. Siegle GJ, Carter CS, Thase ME. Use of FMRI to predict recovery from unipolar depression with cognitive behavior therapy. Am J Psychiatry 2006; 163(4): 735-8.
84. Bremner JD, Innis RB, Salomon RM, Staib LH, Ng CK, Miller HL, et al. Positron emission tomography measurement of cerebral metabolic correlates of tryptophan depletion-induced depressive relapse. Arch Gen Psychiatry 1997; 54(4): 364-74.
85. Lesch KP, Mossner R. Genetically driven variation in serotonin uptake: is there a link to affective spectrum, neurodevelopmental, and neurodegenerative disorders? Biol Psychiatry 1998; 44(3): 179-92.
86. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003; 301(5631): 386-9.
87. Canli T, Qiu M, Omura K, Congdon E, Haas BW, Amin Z, et al. Neural correlates of epigenesis. Proc Natl Acad Sci USA 2006; 103(43): 16033-8.
88. Rao H, Gillihan SJ, Wang J, Korczykowski M, Sankoorikal GM, Kaercher KA, et al. Genetic variation in serotonin transporter alters resting brain function in healthy individuals. Biol Psychiatry 2007; 62(6): 600-6.
89. Bertolino A, Arciero G, Rubino V, Latorre V, De Candia M, Mazzola V, et al. Variation of human amygdala response during threatening stimuli as a function of 5′HTTLPR genotype and personality style. Biol Psychiatry 2005; 57(12): 1517-25.
90. Canli T, Congdon E, Todd Constable R, Lesch KP. Additive effects of serotonin transporter and tryptophan hydroxylase-2 gene variation on neural correlates of affective processing. Biol Psychol 2008; 79(1): 118-25.
91. Heinz A, Braus DF, Smolka MN, Wrase J, Puls I, Hermann D, et al. Amygdala-prefrontal coupling depends on a genetic variation of the serotonin transporter. Nat Neurosci 2005; 8(1): 20-1.
92. Hariri AR, Drabant EM, Munoz KE, Kolachana BS, Mattay VS, Egan MF, et al. A susceptibility gene for affective disorders and the response of the human amygdala. Arch Gen Psychiatry 2005; 62(2): 146-52.
93. Dannlowski U, Ohrmann P, Bauer J, Deckert J, Hohoff C, Kugel H, et al. 5-HTTLPR biases amygdala activity in response to masked facial expressions in major depression. Neuropsychopharmacology 2008; 33(2): 418-24.
94. Dannlowski U, Ohrmann P, Bauer J, Kugel H, Baune BT, Hohoff C, et al. Serotonergic genes modulate amygdala activity in major depression. Genes Brain Behav 2007; 6(7): 672-6.
95. Pezawas L, Meyer-Lindenberg A, Drabant EM, Verchinski BA, Munoz KE, Kolachana BS, et al. 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression. Nat Neurosci 2005; 8(6): 828-34.
96. Pezawas L, Meyer-Lindenberg A, Goldman AL, Verchinski BA, Chen G, Kolachana BS, et al. Evidence of biologic epistasis between BDNF and SLC6A4 and implications for depression. Mol Psychiatry 2008; 13(7): 709-16.
97. Domschke K, Dannlowski U, Ohrmann P, Lawford B, Bauer J, Kugel H, et al. Cannabinoid receptor 1 (CNR1) gene: impact on antidepressant treatment response and emotion processing in major depression. Eur Neuropsychopharmacol 2008; 18(10): 751-9.
98. Viviani R, Sim EJ, Lo H, Richter S, Haffer S, Osterfeld N, et al. Components of variance in brain perfusion and the design of studies of individual differences: The baseline study. . NeuroImage 2009; 46(1): 12-22.
99. Viviani R, Beschoner P, Jaeckle T, Hipp P, Kassubek J, Schmitz B. The bootstrap and cross-validation in neuroimaging applications: estimation of the distribution of extrema of random fields for single volume tests, with an application to ADC maps. Hum Brain Mapp 2007; 28(10): 1075-88.
100. Kirchheiner J, Seeringer A. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. Biochim Biophys Acta 2007; 1770(3): 489-94.
101. Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004; 9(5): 442-73.
102. Bambico FR, Duranti A, Tontini A, Tarzia G, Gobbi G. Endocannabinoids in the treatment of mood disorders: evidence from animal models. Curr Pharm Des 2009; 15(14): 1623-46.
103. Berrocoso E, Sanchez-Blazquez P, Garzon J, Mico JA. Opiates as antidepressants. Curr Pharm Des 2009; 15(14): 1612-22.
104. Lopez-Munoz F, Alamo C. Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. Curr Pharm Des 2009; 15(14): 1563-86.